Early-stage trial to evaluate safety and immunogenicity.
This trial is enrolling adult volunteers in the Atlanta, Cincinnati, Nashville and Seattle areas. At this time, the research sites anticipate they will have an adequate number of volunteers for this study. People who live outside of these regions will not be eligible to participate in this trial.